Firebrick Pharma Limited announced that its Phase 3 clinical trial of Nasodine Nasal Spray ("Nasodine") as a treatment for the common cold has received the necessary ethics approvals to re-open for the 2023 common cold season. Two clinical sites in Australia are now open for recruitment and three sites in South Africa will be open in the next week. This trial was 50% recruited in 2022 and then paused over the summer months, with the stated goal of re-opening in March 2023.

This target has been achieved. The primary endpoint population for the trial is 196 adult subjects with confirmed viral colds. The trial enrolled 100 subjects with confirmed viral colds in 2022, so the goal in 2023 is to enrol the remaining 96 subjects and then report trial results.

In Australia, the trial is taking place at Barwon Health (Geelong) and CMAX (Adelaide).